Premier Alternatives

Alchemab Therapeutics

Drug Discovery · London, United Kingdom · Founded 2019 · Privately Held (backing)

Developer of natural protective antibodies designed to keep people free of hard-to-treat diseases in a transformative approach. Alchemab Therapeutics is based in London, United Kingdom and was founded in 2019. It was valued at $138 million at its later-stage round in Sep 2025, the last priced event on record. It has raised $32.1 million across 1 recorded round; the latest was a $31.9 million Series A in Sep 2025.

PMV mark · valuation
$138.0M
Oct 2026
Priced at
its later-stage round
Sep 2025
Total raised
$32.1M
Last round
Later Stage VC (Series A)
Sep 2025

Alchemab Therapeutics key facts

as of Oct 2026
  • Developer of natural protective antibodies designed to keep people free of hard-to-treat diseases in a transformative approach.
  • Alchemab Therapeutics is valued at approximately $138.0M as of Oct 2026, set at its later-stage round, Sep 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $32.1M across 1 recorded rounds; the latest was Later Stage VC (Series A) ($31.9M) in Sep 2025.
  • Notable investors include Innovate UK, RA Capital Management, DCVC, SV Health Investors, Camford Capital — 11 tracked in total.
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$138.0M

Valued at $138.0M at its later-stage round, Sep 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Alchemab Therapeutics with a free account
  • ·The complete investor list: 11 names
  • ·Watch Alchemab Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Alchemab Therapeutics funding rounds

1 rounds
Sep 2025Later Stage VC (Series A)$31.9M▮
Full funding history →

Alchemab Therapeutics valuation

Alchemab Therapeutics was valued at $138 million at its later-stage round in Sep 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Alchemab Therapeutics raised?

Alchemab Therapeutics has raised $32.1 million across 1 recorded round since 2025. The largest was a $31.9 million Series A in Sep 2025.

Alchemab Therapeutics investors

11 investors are on record for Alchemab Therapeutics, including Innovate UK, RA Capital Management, DCVC and SV Health Investors. By type, the record holds 6 venture capital firms and 1 asset manager. The Series A in Sep 2025 drew 6 investors.

Comparable companies

Comparable drug discovery names by valuation on PrivateMarketView: Sparrow Pharmaceuticals ($139 million), Imbria Pharmaceuticals ($132 million) and Tahoe ($131 million).

About Alchemab Therapeutics

Developer of natural protective antibodies designed to keep people free of hard-to-treat diseases in a transformative approach. The company's antibodies are found through an unbiased and function-first approach using three complementary processes and technologies, enabling patients to control the power of naturally protective antibodies and get themselves treated.

Industry
Drug Discovery
Sector
Healthcare
HQ
London, United Kingdom
Founded
2019
Employees
60
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.